![Stephane van Rooijen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephane van Rooijen
Chief Executive Officer at Dynacure SA
Stephane van Rooijen active positions
Companies | Position | Start | End |
---|---|---|---|
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Director/Board Member | 01/01/2016 | - |
Chief Executive Officer | 01/01/2016 | - | |
Viropharma Ltd.
![]() Viropharma Ltd. Pharmaceuticals: MajorHealth Technology Viropharma Ltd. manufactures pharmaceutical products. The company was founded on May 14, 2007 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/01/2014 | - |
Flamingo Therapeutics BV
![]() Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Director/Board Member | - | - |
Chief Executive Officer | 01/01/2023 | - | |
President | - | - |
Career history of Stephane van Rooijen
Former positions of Stephane van Rooijen
Companies | Position | Start | End |
---|---|---|---|
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Chief Executive Officer | 01/01/2014 | 01/01/2016 |
Training of Stephane van Rooijen
Erasmus University Rotterdam | Masters Business Admin |
Katholieke Universiteit Leuven | Doctorate Degree |
Statistics
International
Belgium | 4 |
Netherlands | 2 |
United Kingdom | 2 |
Operational
Chief Executive Officer | 3 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sectoral
Consumer Services | 3 |
Health Technology | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Viropharma Ltd.
![]() Viropharma Ltd. Pharmaceuticals: MajorHealth Technology Viropharma Ltd. manufactures pharmaceutical products. The company was founded on May 14, 2007 and is headquartered in London, the United Kingdom. | Health Technology |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Flamingo Therapeutics BV
![]() Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
- Stock Market
- Insiders
- Stephane van Rooijen
- Experience